

Fernando Rivera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5834171/publications.pdf>

Version: 2024-02-01

45
papers

12,159
citations

293460

24
h-index

242451

47
g-index

48
all docs

48
docs citations

48
times ranked

12577
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and ≥ 3 baseline circulating tumour cells: the randomised phase II VISNÅ-2 study. ESMO Open, 2021, 6, 100062.	2.0	5
2	Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. Clinical and Translational Oncology, 2020, 22, 1049-1058.	1.2	0
3	Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Annals of Oncology, 2020, 31, 79-87.	0.6	36
4	Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. Annals of Oncology, 2020, 31, 246-256.	0.6	20
5	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clinical Colorectal Cancer, 2019, 18, 245-256.e5.	1.0	2
6	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. International Journal of Cancer, 2019, 145, 576-585.	2.3	21
7	Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. ESMO Open, 2018, 3, e000297.	2.0	18
8	Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer, 2018, 21, 96-105.	2.7	16
9	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. Journal of Cancer Research and Clinical Oncology, 2018, 144, 321-335.	1.2	27
10	First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. European Journal of Cancer, 2018, 101, 263-272.	1.3	58
11	SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer. Clinical and Translational Oncology, 2017, 19, 135-148.	1.2	3
12	Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease, 2017, 32, 1179-1190.	1.0	96
13	Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. Clinical and Translational Oncology, 2017, 19, 508-518.	1.2	13
14	On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1379-1388.	2.3	19
15	SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clinical and Translational Oncology, 2016, 18, 1179-1186.	1.2	24
16	A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2016, 67, 11-20.	1.3	58
17	Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Medicine, 2016, 5, 3464-3474.	1.3	10
18	Seom guidelines for the treatment of gastric cancer 2015. Clinical and Translational Oncology, 2015, 17, 996-1004.	1.2	25

#	ARTICLE	IF	CITATIONS
19	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2015, 51, 942-949.	1.3	47
20	Phase II trial of miniDOX (reduced dose docetaxel+oxaliplatin+capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 319-324.	1.1	16
21	Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. <i>Drugs</i> , 2015, 75, 731-748.	4.9	18
22	PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2240-2247.	0.8	573
23	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2014, 25, 1346-1355.	0.6	462
24	A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond. <i>Cancer Letters</i> , 2014, 351, 30-40.	3.2	56
25	Panitumumab+ FOLFOX4 Treatment and KRAS Mutations in Colorectal Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 1023-1034.	13.9	1,971
26	SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 528-535.	1.2	16
27	Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico. <i>Revista Española De Patología</i> , 2011, 44, 32-48.	0.6	6
28	Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 75-82.	1.1	3
29	Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 179-184.	1.2	75
30	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. <i>Annals of Oncology</i> , 2011, 22, 1078-1087.	0.6	204
31	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. <i>Annals of Oncology</i> , 2010, 21, 1537-1545.	0.6	77
32	Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2010, 21, 1967-1973.	0.6	99
33	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4697-4705.	0.8	1,644
34	Current situation of zalutumumab. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 667-674.	1.4	15
35	Recommendations on current approach to gastric cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 518-525.	1.2	3
36	Phase II Trial of Preoperative Irinotecan+ Cisplatin Followed by Concurrent Irinotecan+ Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1430-1436.	0.4	34

#	ARTICLE	IF	CITATIONS
37	Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1421-1428.	1.1	99
38	Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 253-261.	1.1	8
39	Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 1116-1127.	13.9	3,112
40	Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2013-2019.	0.8	2,735
41	Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. <i>Acta Oncológica</i> , 2008, 47, 9-19.	0.8	83
42	Cetuximab, its clinical use and future perspectives. <i>Anti-Cancer Drugs</i> , 2008, 19, 99-113.	0.7	56
43	Chemotherapy of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2007, 33, 315-324.	3.4	124
44	Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 2866-2872.	0.8	160
45	Long-Term Results of a Phase II Trial of Induction Chemotherapy with Uracil-Ftegafur (UFT), Vinorelbine, and Cisplatin (UFTVP) followed by Radiotherapy Concomitant with UFT and Carboplatin (RT/UFTI) in a Primary Site Preservation Setting for Resectable Locally Advanced Squamous Cell Carcinoma of Larynx and Hypopharynx. <i>Laryngoscope</i> , 2004, 114, 1163-1169.	1.1	7